Abstract
Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Current Medicinal Chemistry
Title: Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia
Volume: 11 Issue: 3
Author(s): C. Simon Sebastian, William Glazer and Peter F. Buckley
Affiliation:
Keywords: Naturalistic, antipsychotics, schizophrenia, placebo-controlled
Abstract: Undoubtedly, the pharmacological treatment of schizophrenia has changed dramatically over the last 10 years. Large, double-blind, placebo-controlled trials have ushered the availability of each new antipsychotic. However, there has been an information lag because of the relative paucity of long term, comparative studies among second-generation antipsychotics. While we await such evidence, naturalistic studies have helped to provide useful information on the pattern of use, patient response, and tolerability of these new agents in clinical practice. This review provides an account of representative studies for each second generation antipsychotic, which illustrate the contributions of naturalistic studies to our understanding of the evolving pharmacotherapy of schizophrenia.
Export Options
About this article
Cite this article as:
Sebastian Simon C., Glazer William and Buckley F. Peter, Naturalistic Studies of Second Generation Antipsychotics in the Treatment of Schizophrenia, Current Medicinal Chemistry 2004; 11 (3) . https://dx.doi.org/10.2174/0929867043456025
DOI https://dx.doi.org/10.2174/0929867043456025 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of MRI Guided Focused Ultrasound Thalamotomy for Parkinson’s Disease: A Review
Current Medical Imaging Neuroprotection and Hypothermia in Infants and Children
Current Drug Targets Fibroblast Growth Factors, Fibroblast Growth Factor Receptors, Diseases, and Drugs
Recent Patents on Cardiovascular Drug Discovery A Case of Akathisia induced by Escitalopram: Case Report & Review of Literature
Current Drug Safety Glycine Site Modulators and Glycine Transporter-1 Inhibitors as Novel Therapeutic Targets for the Treatment of Schizophrenia
Current Neuropharmacology An Update on Adenosine A2A Receptors as Drug Target in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Pharmacotherapy of Schizophrenia: The Past, Present and Future
Current Drug Therapy Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology GDNF Family Ligands: A Potential Future for Parkinson's Disease Therapy
CNS & Neurological Disorders - Drug Targets Advances in Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 1: Overview of the Chemical and Biological Research
Current Drug Targets Current Pharmaceutical Treatments and Alternative Therapies of Parkinson’s Disease
Current Neuropharmacology Data Visualization and Feature Selection Methods in Gel-based Proteomics
Current Protein & Peptide Science Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology Kynurenines in the Central Nervous System: Recent Developments
Central Nervous System Agents in Medicinal Chemistry Domperidone in Parkinson’s Disease: A Perilous Arrhythmogenic or the Gold Standard?
Current Drug Safety Role of Vitamin E in Cellular Antioxidant Defense
Current Chemical Biology The Changing Landscape of Voltage-Gated Calcium Channels in Neurovascular Disorders and in Neurodegenerative Diseases
Current Neuropharmacology Gut-brain Axis: Role of Lipids in the Regulation of Inflammation, Pain and CNS Diseases
Current Medicinal Chemistry Effects of Yokukansan, a Japanese Kampo Medicine for Symptoms Associated Autism Spectrum Disorder
CNS & Neurological Disorders - Drug Targets Pharmacogenetic and Pharmacogenomic Research in Psychiatry: Current Advances and Clinical Applications
Current Pharmacogenomics